Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine
tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose,
randomized, 2-treatment, 2-period, 2-sequence crossover design.